{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:12:50Z","timestamp":1783955570020,"version":"3.55.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"S1","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Historical data for older men with high-risk nonmetastatic prostate cancer treated with radiotherapy alone have demonstrated a 10-year prostate-cancer-specific mortality of around 30%. The development of dose escalation, using techniques such as intensity-modulated radiotherapy, has enabled more targeted delivery of treatment with improved efficacy and a reduction in the risk of toxicity compared with conventional radiotherapy. The combination of radiotherapy and androgen-deprivation therapy (ADT) has been shown to improve overall survival compared with radiotherapy or ADT alone without a significant increase in toxicity in patients with minimal comorbidities. There is evidence that patient age has only a marginal effect on genitourinary and gastrointestinal toxicities following radiotherapy. Further research has shown that although age does have an effect on the likelihood of sexual dysfunction after radiation therapy, there is no significant difference in the proportion of men aged \u226575 years who feel that sexual dysfunction is a moderate or serious problem before or 24 months after diagnosis. Radical radiotherapy is effective and well tolerated in senior men with high-risk prostate cancer and should be offered in combination with long-term ADT to patients with minimal comorbidities. In case of significant comorbid conditions, shorter durations of ADT may be considered.<\/jats:p>","DOI":"10.1634\/theoncologist.2012-s1-09","type":"journal-article","created":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T22:20:08Z","timestamp":1348611608000},"page":"9-15","source":"Crossref","is-referenced-by-count":8,"title":["Radical Radiotherapy for High-Risk Prostate Cancer in Older Men"],"prefix":"10.1093","volume":"17","author":[{"given":"Heather A.","family":"Payne","sequence":"first","affiliation":[{"name":"a University College London Hospitals, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Hughes","sequence":"additional","affiliation":[{"name":"b Oncology Department, Guy's and St Thomas' NHS Trust, London, United Kingdom;"},{"name":"c Department of Imaging Sciences, King's College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,9,1]]},"reference":[{"key":"2021122308383890900_B1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1464-410X.2007.07410.x","article-title":"Radical prostatectomy in men aged \u226570 years: Effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram","volume":"101","author":"Richstone","year":"2008","journal-title":"BJU Int"},{"key":"2021122308383890900_B2","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/j.juro.2009.07.034","article-title":"Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras","volume":"182","author":"Sun","year":"2009","journal-title":"J Urol"},{"key":"2021122308383890900_B3","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/j.1464-410X.2010.09295.x","article-title":"Laparoscopic radical prostatectomy is feasible and effective in \u201cfit\u201d senior men with localized prostate cancer","volume":"106","author":"Sanchez-Salas","year":"2010","journal-title":"BJU Int"},{"key":"2021122308383890900_B4","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1001\/jama.293.17.2095","article-title":"20-year outcomes following conservative management of clinically localized prostate cancer","volume":"291","author":"Albertsen","year":"2005","journal-title":"JAMA"},{"key":"2021122308383890900_B5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00000478-199603000-00004","article-title":"Prediction of progression following radical prostatectomy: A multivariate analysis of 721 men with long-term follow-up","volume":"20","author":"Epstein","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"2021122308383890900_B6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1464-410X.2007.07488.x","article-title":"Localized prostate cancer: Can we better define who is at risk of unfavourable outcome?","volume":"101","author":"Joniau","year":"2008","journal-title":"BJU Int"},{"key":"2021122308383890900_B7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1464-410X.2010.09514.x","article-title":"Trends in the treatment of localized prostate cancer using supplemented cancer registry data","volume":"107","author":"Hamilton","year":"2011","journal-title":"BJU Int"},{"key":"2021122308383890900_B8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.pcan.4500868","article-title":"Greater influence of age than co-morbidity on primary treatments and complications of prostate cancer patients: An in-depth population-based study","volume":"9","author":"Houterman","year":"2006","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2021122308383890900_B9","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.285.21.2750","article-title":"Cancer screening in elderly patients: A framework for individualized decision making","volume":"285","author":"Walter","year":"2001","journal-title":"JAMA"},{"key":"2021122308383890900_B10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1464-410X.2010.09334.x","article-title":"Management of prostate cancer in older men: Recommendations of a working group of the International Society of Geriatric Oncology","volume":"106","author":"Droz","year":"2010","journal-title":"BJU Int"},{"key":"2021122308383890900_B11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.critrevonc.2009.09.005","article-title":"Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults","volume":"73","author":"Droz","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"issue":"suppl 1","key":"2021122308383890900_B12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1634\/theoncologist.2012-S1-31","article-title":"A comment on the International Society of Geriatric Oncology guidelines: Evidence-based advice for the clinical setting","volume":"17","author":"Fitzpatrick","year":"2012","journal-title":"The Oncologist"},{"key":"2021122308383890900_B13","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1200\/JCO.2003.09.034","article-title":"Do older men benefit from curative therapy of localized prostate cancer?","volume":"21","author":"Alibhai","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122308383890900_B14","volume-title":"Guidelines on prostate cancer","author":"Heidenreich","year":"2008"},{"key":"2021122308383890900_B15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<989::AID-CNCR26>3.0.CO;2-Q","article-title":"Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma","volume":"83","author":"Ragde","year":"1998","journal-title":"Cancer"},{"key":"2021122308383890900_B16","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1200\/JCO.2003.01.075","article-title":"Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era","volume":"21","author":"D'Amico","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122308383890900_B17","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308383890900_B18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M.D. Anderson randomized dose-escalation trial for the prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308383890900_B19","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ijrobp.2008.10.091","article-title":"Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials","volume":"74","author":"Viani","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308383890900_B20","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.eururo.2011.08.029","article-title":"Dose escalation for prostate cancer radiotherapy: Predictors of long-term biochemical tumor control and distant metastases-free survival outcomes","volume":"60","author":"Zelefsky","year":"2011","journal-title":"Eur Urol"},{"key":"2021122308383890900_B21","volume-title":"Guidelines on prostate cancer","author":"Heidenreich","year":"2012"},{"key":"2021122308383890900_B22","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308383890900_B23","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308383890900_B24","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122308383890900_B25","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2008.17.4052","article-title":"Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: A secondary analysis of RTOG 85-31","volume":"27","author":"Souhami","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308383890900_B26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","article-title":"Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): An open randomised phase III trial","volume":"373","author":"Widmark","year":"2009","journal-title":"Lancet"},{"key":"2021122308383890900_B27","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","article-title":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet"},{"key":"2021122308383890900_B28","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122308383890900_B29","first-page":"53","article-title":"Potential side effects of androgen deprivation treatment in sex offenders","volume":"37","author":"Giltay","year":"2009","journal-title":"J Am Acad Psychiatry Law"},{"key":"2021122308383890900_B30","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308383890900_B31","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1002\/cncr.26623","article-title":"Androgen deprivation and thromboembolic events in men with prostate cancer","volume":"118","author":"Ehdaie","year":"2011","journal-title":"Cancer"},{"key":"2021122308383890900_B32","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","article-title":"Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions","volume":"25","author":"D'Amico","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308383890900_B33","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1464-410X.2010.09273.x","article-title":"Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke","volume":"106","author":"Hayes","year":"2010","journal-title":"BJU Int"},{"key":"2021122308383890900_B34","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.eururo.2011.08.041","article-title":"Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer","volume":"60","author":"Azoulay","year":"2011","journal-title":"Eur Urol"},{"key":"2021122308383890900_B35","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.ijrobp.2011.04.067","article-title":"Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction","volume":"82","author":"Nguyen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308383890900_B36","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/jcem.86.2.7219","article-title":"longitudinal effects of aging on serum total and free testosterone levels in healthy men","volume":"86","author":"Harman","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122308383890900_B37","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2008.01.021","article-title":"Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02","volume":"54","author":"Efstathiou","year":"2008","journal-title":"Eur Urol"},{"key":"2021122308383890900_B38","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","article-title":"Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31","volume":"27","author":"Efstathiou","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308383890900_B39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(11)70063-8","article-title":"Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial","volume":"12","author":"Denham","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122308383890900_B40","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"issue":"suppl","key":"2021122308383890900_B41","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.eursup.2010.08.002","article-title":"Prostate cancer management: What does the future hold?","volume":"9","author":"Tombal","year":"2010","journal-title":"Eur Urol"},{"key":"2021122308383890900_B42","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.urology.2007.09.066","article-title":"Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer","volume":"71","author":"Bong","year":"2008","journal-title":"Urology"},{"key":"2021122308383890900_B43","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","article-title":"Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial","volume":"8","author":"Dearnaley","year":"2007","journal-title":"Lancet Oncol"},{"key":"2021122308383890900_B44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14470","article-title":"Intensity-modulated radiotherapy for the treatment of prostate cancer: A systematic review and economic evaluation","volume":"14","author":"Hummel","year":"2010","journal-title":"Health Technol Assess"},{"key":"2021122308383890900_B45","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.clon.2010.06.013","article-title":"A review of the clinical evidence for intensity-modulated radiotherapy","volume":"22","author":"Staffurth","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2021122308383890900_B46","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.3390\/cancers3033419","article-title":"Toxicity and long-term outcomes of dose-escalated intensity modulated radiation therapy to 74GY for localised prostate cancer in a single Australian centre","volume":"3","author":"Sia","year":"2011","journal-title":"Cancers"},{"key":"2021122308383890900_B47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1548-5315(11)70898-1","article-title":"Defining targets and protecting normal tissues in inverse-planned IMRT for prostate, head and neck, and gynecologic cancers: A comparative review","volume":"2","author":"Dragun","year":"2005","journal-title":"Community Oncol"},{"key":"2021122308383890900_B48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijrobp.2010.09.058","article-title":"Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity","volume":"82","author":"Pederson","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308383890900_B49","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/jjco\/hyl002","article-title":"Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: Comparison with conventional and conformal radiotherapy","volume":"36","author":"Namiki","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"2021122308383890900_B50","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.ijrobp.2006.11.014","article-title":"Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: Results from the Dutch trial of 68 Gy versus 78 Gy","volume":"67","author":"Heemsbergen","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308383890900_B51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(11)70293-5","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: Preliminary results from the CHHiP randomised controlled trial","volume":"13","author":"Dearnaley","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122308383890900_B52","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u00df = 1.4 (0.9\u20132.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308383890900_B53","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijrobp.2006.12.036","article-title":"Use of individual fraction size data from 3756 patients to directly determine the \u03b1\/\u00df ratio of prostate cancer","volume":"68","author":"Williams","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308383890900_B54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijrobp.2009.01.062","article-title":"Long-term toxicity following 3D conformal radiation therapy for prostate cancer on RTOG 9406, a phase I\/II dose escalation study","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122308383890900_B55","first-page":"289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial","volume":"299","author":"D'Amico","year":"2008","journal-title":"JAMA"},{"key":"2021122308383890900_B56","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.urology.2004.12.041","article-title":"Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer","volume":"65","author":"Jani","year":"2005","journal-title":"Urology"},{"key":"2021122308383890900_B57","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1200\/JCO.2001.19.9.2517","article-title":"Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study","volume":"19","author":"Hamilton","year":"2001","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2012-S1-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2012-S1-09","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/S1\/9\/41858464\/oncolo_17_s1_9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/S1\/9\/41858464\/oncolo_17_s1_9.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T01:06:18Z","timestamp":1640307978000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/S1\/9\/6400881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,1]]},"references-count":57,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2012,9,1]]},"published-print":{"date-parts":[[2012,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2012-s1-09","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,9,1]]},"published":{"date-parts":[[2012,9,1]]}}}